PNEX.D Stock Overview
Pharnext SA, a clinical-stage biopharmaceutical company, engages in the development of therapies for neurodegenerative diseases with high unmet medical needs.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Pharnext SA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €0.50 |
52 Week High | €550.00 |
52 Week Low | €0.50 |
Beta | 1.76 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | -100.00% |
5 Year Change | n/a |
Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
PNEX.D | US Biotechs | US Market | |
---|---|---|---|
7D | 0% | 0.9% | 0.4% |
1Y | n/a | 10.3% | 28.8% |
Return vs Industry: Insufficient data to determine how PNEX.D performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how PNEX.D performed against the US Market.
Price Volatility
PNEX.D volatility | |
---|---|
PNEX.D Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PNEX.D's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine PNEX.D's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | n/a | Joshua Schafer | https://pharnext.com |
Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company’s products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer’s disease, as well as Parkinson’s disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform.
Pharnext SA Fundamentals Summary
PNEX.D fundamental statistics | |
---|---|
Market cap | US$270.08k |
Earnings (TTM) | -US$38.34m |
Revenue (TTM) | US$2.89m |
0.1x
P/S Ratio0.0x
P/E RatioIs PNEX.D overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PNEX.D income statement (TTM) | |
---|---|
Revenue | €2.72m |
Cost of Revenue | €0 |
Gross Profit | €2.72m |
Other Expenses | €38.90m |
Earnings | -€36.17m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -9.20 |
Gross Margin | 100.00% |
Net Profit Margin | -1,328.79% |
Debt/Equity Ratio | -85.6% |
How did PNEX.D perform over the long term?
See historical performance and comparison